BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 25956579)

  • 1. Surgical Management of Breast Cancer in 2010-2011 SEER Registries by Hormone and HER2 Receptor Status.
    Lizarraga I; Schroeder MC; Weigel RJ; Thomas A
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S566-72. PubMed ID: 25956579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Receptor Status on Mastectomy and Contralateral Prophylactic Mastectomy Rates in Early Stage Invasive Breast Carcinoma.
    Dutta SW; Trifiletti DM; Grover S; Romano KD; Janowski EM; Showalter SL
    Clin Breast Cancer; 2018 Apr; 18(2):121-127. PubMed ID: 28811185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Significance of Tumor Subtypes in Women With Breast Cancer According to Stage: A Population-based Study.
    Leone JP; Leone J; Zwenger AO; Vallejo CT; Leone BA
    Am J Clin Oncol; 2019 Jul; 42(7):588-595. PubMed ID: 31166208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016.
    Thomas A; Rhoads A; Suhl J; Conway KM; Hundley WG; McNally LR; Oleson J; Melin SA; Lynch CF; Romitti PA
    Clin Breast Cancer; 2020 Aug; 20(4):e410-e422. PubMed ID: 32278642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database.
    Hwang KT; Kim J; Jung J; Chang JH; Chai YJ; Oh SW; Oh S; Kim YA; Park SB; Hwang KR
    Clin Cancer Res; 2019 Mar; 25(6):1970-1979. PubMed ID: 30559169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer.
    Ogiya R; Sagara Y; Niikura N; Freedman RA
    Clin Breast Cancer; 2019 Jun; 19(3):200-207.e1. PubMed ID: 30795886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy use and surgical treatment by receptor subtype in node-negative T1a and T1b female breast cancers, Iowa SEER Registry, 2010 to 2012.
    Schroeder MC; Lynch CF; Abu-Hejleh T; Chrischilles EA; Thomas A
    Clin Breast Cancer; 2015 Feb; 15(1):e27-34. PubMed ID: 25245424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer.
    Pesce C; Liederbach E; Wang C; Lapin B; Winchester DJ; Yao K
    Ann Surg Oncol; 2014 Oct; 21(10):3231-9. PubMed ID: 25081341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contralateral prophylactic mastectomy and its association with reduced mortality: evidence for selection bias.
    Jatoi I; Parsons HM
    Breast Cancer Res Treat; 2014 Nov; 148(2):389-96. PubMed ID: 25301088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Breast Cancer Subtype Defined by Immunohistochemistry Hormone Receptor and HER2 Status on the Incidence of Immediate Postmastectomy Reconstruction.
    Wu W; Cheng S; Deng H; Wu J; Mao K; Cao M
    Medicine (Baltimore); 2016 Jan; 95(3):e2547. PubMed ID: 26817902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing national mastectomy rates for the treatment of early stage breast cancer.
    Mahmood U; Hanlon AL; Koshy M; Buras R; Chumsri S; Tkaczuk KH; Cheston SB; Regine WF; Feigenberg SJ
    Ann Surg Oncol; 2013 May; 20(5):1436-43. PubMed ID: 23135312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact of Discordance in Hormone Receptor Status Between Primary and Recurrent Sites in Patients With Recurrent Breast Cancer.
    Shiino S; Kinoshita T; Yoshida M; Jimbo K; Asaga S; Takayama S; Tsuda H
    Clin Breast Cancer; 2016 Aug; 16(4):e133-40. PubMed ID: 27268749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
    Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
    Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
    Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.